See more : FTAI Aviation Ltd. (FTAI) Income Statement Analysis – Financial Results
Complete financial analysis of QSAM Biosciences, Inc. (QSAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of QSAM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China New City Commercial Development Limited (1321.HK) Income Statement Analysis – Financial Results
- Entergy Corporation (0IHP.L) Income Statement Analysis – Financial Results
- PropTech Investment Corporation II (PTIC) Income Statement Analysis – Financial Results
- Schaeffler AG (SCFLF) Income Statement Analysis – Financial Results
- INDUS Holding AG (INDHF) Income Statement Analysis – Financial Results
QSAM Biosciences, Inc. (QSAM)
About QSAM Biosciences, Inc.
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 916.67K | 33.33K | 74.76K | 40.00K | 20.00K | 0.00 | 3.61K | 428.86K | 85.97K | 115.28K | 71.96K | 486.57K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 372.94B | 354.00 | 0.00 | 63.30K | 7.17K | 5.80K | 2.46K | 1.04K | 292.96K | 77.61K | 139.54K | 116.01K | 761.56K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -372.94B | 916.31K | 33.33K | 11.46K | 32.83K | 14.20K | -2.46K | 2.57K | 135.90K | 8.36K | -24.25K | -44.05K | -275.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 99.96% | 100.00% | 15.33% | 82.07% | 70.99% | 0.00% | 71.29% | 31.69% | 9.72% | -21.04% | -61.22% | -56.52% | 0.00% |
| Research & Development | 1.16M | 1.02M | 647.30K | 362.46K | 0.00 | 0.00 | 0.00 | 352.58K | 1.42M | 12.88K | 9.30K | 295.12K | 433.56K | 500.11K | 431.90K | 844.11K | 0.00 |
| General & Administrative | 1.78K | 4.44M | 10.39M | 961.94K | 2.08M | 1.61M | 1.34M | 1.73M | 1.98M | 4.52M | 44.82K | 1.55M | 1.98M | 0.00 | 0.00 | 2.43M | 74.60K |
| Selling & Marketing | -1,780.81B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.79K | 339.70K | 0.00 | 0.00 | 10.38K | 20.00K |
| SG&A | 2.78M | 4.44M | 10.39M | 961.94K | 2.08M | 1.61M | 1.34M | 1.73M | 1.98M | 4.52M | 44.82K | 1.81M | 2.32M | 4.04M | 2.17M | 2.44M | 94.60K |
| Other Expenses | 1,001.70B | 2,899.99B | -744.51K | -3.17M | 1.06M | 1.58M | -1.25M | 0.00 | 0.00 | 1.80K | 16.54K | 0.00 | 1.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.94M | 5.46M | 11.04M | 1.32M | 2.08M | 1.61M | 1.34M | 2.08M | 3.40M | 4.54M | 70.65K | 2.10M | 3.92M | 4.54M | 2.60M | 3.29M | 94.60K |
| Cost & Expenses | 3.94M | 5.46M | 11.04M | 1.32M | 2.08M | 1.61M | 1.40M | 2.09M | 3.40M | 4.54M | 71.69K | 2.39M | 4.00M | 4.68M | 2.71M | 4.05M | 94.60K |
| Interest Income | 0.00 | 74.39 | 44.17 | 490.40 | 540.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 17.74K | 17.74K | 20.67K | 0.00 |
| Interest Expense | 52.69K | 74.39K | 788.68K | 490.40K | 556.30K | 346.02K | 345.43K | 226.73K | 19.69K | 47.48K | 170.29K | 931.45K | 111.69K | 23.88K | 23.88K | 110.04K | 0.00 |
| Depreciation & Amortization | 36.30B | 36.30K | 236.56K | -3.17M | 1.06M | 199.00 | 23.13K | 71.27K | 84.25K | 22.55 | 16.54K | 64.49K | 66.96K | 54.54K | 73.24K | 52.17K | 0.00 |
| EBITDA | -3.94M | -5.41M | -11.93M | -5.33M | -93.05K | -1.58M | -1.30M | -1.98M | -3.30M | -480.59K | -4.54M | -1.90M | -2.70M | -2.67M | -4.57M | -2.44M | -94.60K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -11.32% | -3.12% | -3,419.48% | -4,940.10% | -16,502.75% | 0.00% | -1,428.60% | -443.14% | -4,472.86% | -3,590.50% | -3,632.34% | -719.54% | 0.00% |
| Operating Income | -3.94M | -5.46M | -11.04M | -1.32M | -1.16M | -1.58M | -1.33M | -2.05M | -3.38M | -4.54M | -68.08K | -2.70M | -3.91M | -4.57M | -2.64M | -3.56M | -94.60K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -126.76% | -4,733.21% | -1,772.52% | -5,118.28% | -16,924.00% | 0.00% | -1,886.97% | -628.70% | -4,550.76% | -3,962.23% | -3,671.83% | -731.75% | 0.00% |
| Total Other Income/Expenses | -450.62K | -20.11K | -935.80K | -4.50M | 479.99K | 1.18M | -1.39M | 549.59K | -151.22K | 1.02M | -4.68M | -200.17K | -200.17K | 543.89K | -2.31M | 127.87K | 0.00 |
| Income Before Tax | -4.39M | -5.48M | -11.98M | -5.82M | -681.98K | -397.26K | -2.72M | -1.50M | -3.54M | -4.75M | -238.37K | -2.90M | -4.02M | -4.95M | -2.51M | -3.66M | -94.60K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -74.40% | -1,191.78% | -3,635.96% | -3,744.31% | -17,680.11% | 0.00% | -6,606.82% | -675.37% | -4,680.67% | -4,291.97% | -3,494.12% | -751.60% | 0.00% |
| Income Tax Expense | -3.94K | 593.59K | 788.68K | -466.85K | 1.61M | 50.00K | -206.72K | -776.32K | 131.53K | 160.00K | 170.29K | 931.45K | 111.69K | 349.00 | 1.60K | 800.00 | 0.00 |
| Net Income | -4.39M | -6.07M | -12.77M | -5.35M | -2.30M | -397.26K | -2.72M | -1.50M | -3.54M | -4.75M | -238.37K | -2.90M | -4.02M | -4.95M | -2.52M | -3.66M | -94.60K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -250.49% | -1,191.78% | -3,635.96% | -3,744.31% | -17,680.11% | 0.00% | -6,606.82% | -675.37% | -4,680.67% | -4,292.27% | -3,496.35% | -751.77% | 0.00% |
| EPS | -2.88K | -3.45 | -16.13 | -38.77 | -44.16 | -7.97 | -58.25 | -52.67 | -212.02 | -3.05K | -6.61 | -2.44K | -3.85K | -4.63K | -2.20K | -2.94K | -75.92 |
| EPS Diluted | -2.88K | -3.45 | -16.13 | -38.77 | -44.16 | -7.97 | -58.25 | -52.67 | -212.02 | -3.05K | -6.61 | -2.44K | -3.85K | -4.63K | -2.20K | -2.94K | -75.92 |
| Weighted Avg Shares Out | 1.52K | 1.76M | 791.60K | 138.07K | 52.00K | 49.87K | 46.66K | 28.44K | 16.68K | 1.56K | 36.08K | 1.19K | 1.05K | 1.07K | 1.14K | 1.25K | 1.25K |
| Weighted Avg Shares Out (Dil) | 1.52K | 1.76M | 791.60K | 138.07K | 52.00K | 49.87K | 46.66K | 28.44K | 16.68K | 1.56K | 36.08K | 1.19K | 1.05K | 1.07K | 1.14K | 1.25K | 1.25K |
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM's common stock, par value $0.0001...
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM...
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX:...
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with...
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
MELBOURNE, Australia , Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United...
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today issued the following letter to its shareholders.
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug...
QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the countries of Japan...
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of Q SAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:
Source: https://incomestatements.info
Category: Stock Reports